?Effects of herbal product IMPOHelzavid on improving patients with community acquired pneumonia

Evaluation of safety and efficacy of IMPOHelzavid herbal compound on improving the symptoms and complications of patients with community acquired pneumonia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080901001157N18

Enrollment

Registered

2022-03-27

Start date

2022-07-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: community acquired pneumonia. Condition 2: community acquired pneumonia. Condition 3: community acquired pneumonia. Condition 4: community acquired pneumonia. Pneumonia due to Hemophilus influenzae Pneumonia due to Streptococcus pneumoniae Bacterial pneumonia, not elsewhere classified Pneumonia, unspecified organism

Interventions

Intervention 1: Intervention group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the herbal compound two times a day. The herbal capsule contains a

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients infected with community acquired pneumonia Age 20 to 70 years old who have the ability to take oral product Personal desire to participate in the project and the signing of a written consent

Exclusion criteria

Exclusion criteria: Patients with severe dyspnea Patients with reduced level of consciousness or need hospitalization in intensive care units Patients with swallowing disorders or possibility of aspiration of food or unable to take the product orally Patients with respiratory failure require mechanical ventilation Patients with resistant hypoxemia Patients with organ transplantation or malignant disease treated with corticosteroids or chemotherapy Pregnant women Patients with uncontrolled blood pressure, uncontrolled diabetes, cardiovascular disease and underlying respiratory disease

Design outcomes

Secondary

Measure	Time frame
Fever. Timepoint: At beginning and then every 12 hours up to end of the study. Method of measurement: Termometer.;ALT. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Aspartate transaminase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Alkaline phosphatase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Creatinine. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;BUN. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;ESR. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;CBC. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;C-reactive protein. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Alanine transaminase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Mortality rate. Timepoint: During the study. Method of measurement: Number.;Hospitalization. Timepoint: During the study. Method of measurement: Number.	—

Measure

Time frame

Fever. Timepoint: At beginning and then every 12 hours up to end of the study. Method of measurement: Termometer.;ALT. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Aspartate transaminase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Alkaline phosphatase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Creatinine. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;BUN. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;ESR. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;CBC. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;C-reactive protein. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Alanine transaminase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Mortality rate. Timepoint: During the study. Method of measurement: Number.;Hospitalization. Timepoint: During the study. Method of measurement: Number.

—

Primary

Measure	Time frame
Blood oxygen saturation. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Pulse Oximeter.;Shortness of breath. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Scoring questionnaire.;Cough. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Scoring questionnaire.	—

Measure

Time frame

Blood oxygen saturation. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Pulse Oximeter.;Shortness of breath. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Scoring questionnaire.;Cough. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Scoring questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Banafshe

kashan University of Medical Science

banafshe57@hotmail.com+98 31 5558 9399

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026